Dr. Makary argues for more humility from the medical establishment and common sense when reviewing experimental drugs for ...
The FDA’s Oncologic Drugs Advisory Committee recently voted to narrow the label for checkpoint inhibitors Keytruda and Opdivo in stomach and esophageal cancers based on PD-L1 expression levels—but the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback